Saqib Islam was appointed Chief Executive Officer of SpringWorks Therapeutics in 2018. He was a founding member of the company’s executive team since its launch in 2017 and previously served as Chief Financial Officer and Chief Business Officer of the company. Prior to joining SpringWorks, Saqib was Chief Business Officer at Moderna Therapeutics, where he oversaw critical aspects of the company’s growth, including global strategic planning, corporate development, and business development. Prior to Moderna, Saqib served as Executive Vice President, Chief Strategy and Portfolio Officer at Alexion Pharmaceuticals, executing the company’s corporate growth strategies and contributing to its assessment and management of global operations. Saqib has over 25 years of international business management experience and an extensive background in the healthcare banking sector, having held managing director positions in the investment banking divisions of Morgan Stanley and Credit Suisse Securities. He currently serve son the Board of Directors of Passage Bio (where he also serves as a member of its Audit Committee) and Silverback Therapeutics (where he also serves as a member of its Compensation Committee). Saqib received his bachelor’s degree from McGill University, graduating as a Faculty and University Scholar, and a J.D. from Columbia Law School, where he was a Harlan Fiske Stone Scholar.